Use of sardine peptide composition in drug for treating allergic rhinitis
Through the synergistic effect of polypeptides of sardine peptide composition, the side effects and treatment problems of existing allergic rhinitis drugs are solved, and a safe and efficient rhinitis treatment plan is provided, which significantly improves the symptoms of allergic rhinitis and avoids side effects.
Patent Information
- Application Number
- PCT/CN2024/091829
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-21
AI Technical Summary
The existing allergic rhinitis drugs have side effects such as intranasal irritation, dryness, burning nose, and nose bleeding, and require continuous use, making it difficult to effectively treat recurrent diseases.
Using sardine peptide composition, the synergistic effect of its anti-allergic short peptide, ACE inhibitory active short peptide and L-type calcium ion channel inhibits the synergistic effect of active peptides, reduces the release of proinflammatory cytokines, inhibits the inflammatory pathway and calcium ion inflow, and prevents Mast cells are degranulated and nasal sprays are prepared in various dosage forms for the treatment of allergic rhinitis.
Significantly improves the symptoms of rhinitis, such as congestion in the nasal capillaries, itchy nose, sneezing, nasal congestion, itchy eyes and watery secretions, and has no local irritation and systemic side effects, which is safe and has significant effect.
Smart Images

Figure CN2024091829_21112024_PF_FP_ABST
Abstract
Description
Application of sardine peptide composition in medicine for treating allergic rhinitis Technical Field
[0001] The invention belongs to the technical field of biomedicine, and particularly relates to application of a sardine peptide composition in medicine for treating allergic rhinitis. Background Art
[0002] Allergic rhinitis (AR), also known as allergic rhinitis, is an inflammatory nasal disease mediated by immunoglobulin E (IgE). It affects approximately 10% of the population and is caused by exposure of sensitive individuals to allergens. Mast cells, eosinophils, CD4+ T lymphocytes, and B lymphocytes are the primary inflammatory cells involved. Mast cell degranulation releases various transmitters, leading to increased microvascular permeability, nasal mucosal edema, and hypersecretion. The release of multiple cytokines is also a key mechanism of tissue damage in allergic rhinitis.
[0003] Angiotensin II (Ang II) is a key component of the renin-angiotensin system (RAS). The majority of Ang II's effects are mediated by AT1. The combination of the two can cause vasoconstriction, increase blood pressure, and produce proinflammatory effects on white blood cells, endothelial cells, and vascular smooth muscle cells. Angiotensin-converting enzyme (ACE) is a zinc metalloproteinase primarily found in pulmonary vascular endothelial cells, but also in most tissues, including the uterus, placenta, heart, blood vessels, kidneys, brain, and adrenal cortex. ACE converts Ang I to Ang II (a vasoconstrictor) and degrades bradykinin (a vasodilator), regulating blood pressure and cardiovascular homeostasis in vivo. Ang II can increase vascular permeability by inducing mast cell degranulation.
[0004] Mast cell (MC) degranulation is a crucial step in allergic reactions, driven by the regulation of calcium influx and activation of calcium signaling pathways. Disodium cromolyn (DSCG), a current allergic rhinitis medication, inhibits mast cell degranulation by limiting the chloride channels that regulate cell volume, preventing extracellular calcium ions from entering the mast cell cytoplasm. DSCG can limit the nasal response to allergens, making it one of the best options for preventing symptom onset. Studies have shown that VY, also known as Val-Tyr, also has calcium channel inhibitory properties, inhibiting extracellular calcium influx.
[0005] Allergic rhinitis is a recurring disease requiring continuous medication. Effective treatment remains a medical challenge. Existing steroidal nasal sprays can cause nasal irritation, dryness, burning sensations, and nosebleeds. Antihistamines can suppress allergic reactions, but they also have drawbacks such as dryness and drowsiness. Therefore, providing a drug that can effectively treat allergic rhinitis is of great practical significance.
[0006] Summary of the Invention
[0007] The present invention proposes the use of a sardine peptide composition in a drug for treating allergic rhinitis. Studies have confirmed that the sardine peptide composition has excellent effectiveness and safety as a therapeutic agent for allergic rhinitis and can significantly improve the symptoms related to rhinitis, especially allergic rhinitis.
[0008] Sardines peptides are a mixture of oligopeptides obtained by processing sardine muscle, with a molecular weight ranging from 200 to 900 Daltons. Currently, sardine peptides are added to foods and health supplements to maintain normal blood pressure. The oligopeptides contained in sardine peptides possess high biological activity and are categorized by function as anti-allergic peptides, ACE inhibitory peptides, and L-type calcium channel inhibitory peptides. The inventors conducted further research on the functions of each active peptide and discovered that anti-inflammatory peptides can prevent and treat inflammation by reducing the release of proinflammatory cytokines and inhibiting or intervening in TNF-α-induced inflammatory pathways, NF-κB, and MAPK signaling pathways. ACE inhibitory peptides suppress inflammation by inhibiting ACE activity and Ang II production. L-type calcium channel inhibitory peptides can inhibit L-type calcium channel activity in cells, thereby inhibiting calcium influx and preventing mast cell degranulation. The physiological mechanisms of these bioactive peptides support the potential of sardine peptides in treating allergic rhinitis or allergic rhinitis symptoms. Based on this, the inventors further discovered that the absorption efficiency of mixed polypeptides is higher than that of single polypeptides, and the biological activities between polypeptides have a synergistic effect, and the biological activity of mixed polypeptides is higher than that of single polypeptides.
[0009] In view of this, the inventors provide the following solutions of the present invention.
[0010] In order to achieve the above-mentioned object of the invention, the first aspect of the present invention provides the use of a sardine peptide composition in a drug for treating allergic rhinitis.
[0011] Furthermore, the sardine peptide composition is prepared from sardines by methods including microbial fermentation, acid method, alkaline method, electrolysis method, artificial grafting method, gene expression method, and enzymatic hydrolysis method. As long as it has biological activity, it is not particularly limited; preferably, the sardine peptide composition is prepared by enzymatic hydrolysis.
[0012] Furthermore, the sardine peptide composition is a mixture of sardine dipeptides to pentapeptides; wherein the sardine dipeptides include Ala-Leu, Lys-Trp, Ala-Trp, Met-Leu, Arg-Tyr, Met-Phe, Gly-Trp, Met-Tyr, Gly-Tyr, Phe-Leu, Ile-Phe, Thr-Tyr, Ile-Trp, Tyr-Leu, Ile-Tyr, Val-Phe, Leu-Trp, Val-Tr p, Leu-Tyr, Val-Tyr; sardine tripeptide includes Ala-Asn-Pro, Ala-Lys-Lys, Arg-Phe-His, Arg-Val-Tyr, Gly-Arg-Pro, Ile-Val-Tyr, Trp-Ile-Thr, Tyr-Val-Pro, Val-Val-Phe; sardine tetrapeptide is Gly-Trp-Ala-Pro; sardine pentapeptide is Asn-Val-Pro-Ile-Tyr.
[0013] Furthermore, the effective dosage of the sardine peptide composition in a diseased body is 0.01 to 0.03 mg / kg.
[0014] A second aspect of the present invention provides a composition for preventing and treating allergic rhinitis, wherein the composition comprises a sardine peptide composition and a pharmaceutically acceptable excipient.
[0015] Furthermore, the sardine peptide composition is a mixture of sardine dipeptides to pentapeptides; wherein the sardine dipeptides include Ala-Leu, Lys-Trp, Ala-Trp, Met-Leu, Arg-Tyr, Met-Phe, Gly-Trp, Met-Tyr, Gly-Tyr, Phe-Leu, Ile-Phe, Thr-Tyr, Ile-Trp, Tyr-Leu, Ile-Tyr, Val-Phe, Leu-Trp, Val-Tr p, Leu-Tyr, Val-Tyr; sardine tripeptide includes Ala-Asn-Pro, Ala-Lys-Lys, Arg-Phe-His, Arg-Val-Tyr, Gly-Arg-Pro, Ile-Val-Tyr, Trp-Ile-Thr, Tyr-Val-Pro, Val-Val-Phe; sardine tetrapeptide is Gly-Trp-Ala-Pro; sardine pentapeptide is Asn-Val-Pro-Ile-Tyr.
[0016] Furthermore, the mass concentration of the sardine peptide composition in the composition can be appropriately selected taking into account symptoms, age, dosage form, etc. Specifically, for nasal drops, the mass concentration of the sardine peptide composition is 0.01% to 50%, preferably 0.15% to 10% (w / w).
[0017] The frequency and duration of use of the composition vary depending on symptoms, age, dosage form, etc., but the standard is 2-3 times a day and the duration of use is 7-14 days.
[0018] Further, the route of administration of the composition can include mucosal administration preparations, gastrointestinal administration preparations, respiratory tract administration preparations, skin administration preparations, cavity administration preparations, and injectable administration preparations according to the patient and symptoms. Specifically, it can be nasal drops, gels, ointments, creams, lotions, sprays, liquid preparations, nasal sprays, patches, aerosols, jellies, cataplasms, patches, plasters, suspensions, emulsions, injections, tablets, pills, capsules, granules, powders, etc. By selecting an appropriate solvent, it can also be used in the form of a liquid preparation. Any preparation can be prepared by known methods.
[0019] Furthermore, the mucosal administration preparation is preferably a nasal preparation or a sublingual tablet, and the nasal preparation includes an ointment, gel, cream, lotion, liquid preparation, powder, oil spray or spray nasal preparation; particularly preferably an oil spray.
[0020] The nasal drops of the present invention can be in the form of liquid preparations or dry products such as powders, and can contain carriers or excipients, surfactants, suspending agents, osmotic pressure regulators, etc. Examples of the nasal drops include sodium chloride, glycerol, sodium bisulfite, benzalkonium chloride, fructose, citric acid, sodium citrate, crystalline sodium dihydrogen phosphate, sodium hydroxide, sorbitol solution, niacinamide, concentrated glycerol, propylene glycol, benzyl alcohol, boric acid, borax, polyethylene glycol 4000, sodium hydroxide, phosphoric acid, sodium dihydrogen phosphate, and potassium dihydrogen phosphate. Suspending agents include crystalline cellulose, sodium carboxymethyl cellulose, and hydroxypropyl cellulose.
[0021] Liquid preparations are prepared by dissolving the active ingredient, a sardine peptide composition, in a matrix of ethanol, glycerol, propylene glycol, polyethylene glycol, water, or fatty oil. Preferably, the liquid preparation comprises an aqueous solution of the sardine peptide composition dissolved in physiological saline. In addition to physiological saline, the aqueous solution may also contain a small amount of an organic solvent such as ethanol, glycerol, propylene glycol, polyethylene glycol, or dimethyl sulfoxide.
[0022] Liquid preparations, in addition to the above-mentioned aqueous solution preparations, can also be in the form of aqueous or oily solutions, suspensions, emulsions, etc. In addition, they can also be provided as dry pharmaceutical compositions that are reconstituted in water or an appropriate medium before use.
[0023] The spray is prepared by preparing the sardine peptide composition into an aqueous solution, an oil solution, an emulsion or a suspension.
[0024] When preparing the rhinitis therapeutic agent of the present invention, various bases, moisturizers, alcohols, chelating agents, pH adjusters, preservatives, thickeners, colorants, fragrances, fillers, excipients, disintegrants, extenders, adhesives, coatings, solubilizers, suspending agents, buffers, stabilizers, antibacterial agents, surfactants, antioxidants, emulsifiers, solubilizers, and cosolvents can be arbitrarily combined and formulated. In addition to the sardine peptide as the active ingredient, various pharmaceutical agents such as vitamins and bactericides can also be formulated as needed.
[0025] Furthermore, the allergic rhinitis is also called allergic rhinitis (AR), including seasonal allergic rhinitis and perennial allergic rhinitis.
[0026] The advantages and beneficial effects of the present invention are:
[0027] 1. The sardine peptide composition of the present invention contains a variety of short peptides with high biological activity. According to their functions, they are divided into anti-allergic active short peptides, ACE inhibitory active short peptides and L-type calcium channel inhibitory active peptides; among them, anti-inflammatory active peptides can achieve the purpose of preventing and treating inflammation by reducing the release of proinflammatory cytokines, inhibiting or intervening in TNF-α-induced inflammatory pathways, NF-κB and MAPK signaling pathways. ACE inhibitory short peptides inhibit ACE activity and AngⅡ production, thereby achieving the purpose of inhibiting inflammation. L-type calcium channel inhibitory active peptides can inhibit cellular L-type calcium channel activity, thereby inhibiting calcium ion influx and preventing mast cell degranulation. The above-mentioned different short peptides in the sardine peptide composition cooperate with each other and exert their respective effects, so that the composition has a significant effect in treating and improving symptoms related to allergic rhinitis.
[0028] 2. The sardine peptide composition of the present invention has a good effect in treating allergic rhinitis or improving symptoms, and can be prepared into a variety of dosage forms for administration.
[0029] 3. The nasal preparation prepared using the sardine peptide composition of the present invention not only alleviates nasal capillary congestion but also effectively alleviates symptoms such as nasal itching, sneezing, rhinorrhoea, and nasal congestion caused by allergic rhinitis, as well as itching of the palate, throat, ears, and eyes, as well as redness, swelling, and watery discharge. Furthermore, it is non-irritating to patients with sensitive nasal mucosa, and no local side effects or systemic side effects such as drowsiness have been observed. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The present invention will be further described below with reference to the accompanying drawings and examples.
[0031] Figure 1 shows the effect of the drug in Test Example 2 on the ciliary movement of the toad's maxillary cilia;
[0032] FIG2 shows a diagram of the ciliary motion state at the initial time of drug administration in Test Example 2;
[0033] FIG3 shows a diagram of the ciliary movement state of Test Example 2 18 hours after administration;
[0034] In the figure, A: physiological saline; B: refined sesame oil; C: sardine peptide nasal spray (oil solution) of Example 4; D: sardine peptide nasal spray (oil solution) of Example 4 + berberine sesame oil suspension. DETAILED DESCRIPTION
[0035] In the following examples, unless otherwise specified, the experimental instruments and raw materials involved are commercially available products.
[0036] Raw materials, see Table 1.
[0037] Table 1
[0038] It has been determined that the sardine peptide composition Valtyron of Japan's Senmi Company is prepared by enzymatic hydrolysis and is a mixture of sardine dipeptides to pentapeptides; among them, sardine dipeptide is a combination of Ala-Leu, Lys-Trp, Ala-Trp, Met-Leu, Arg-Tyr, Met-Phe, Gly-Trp, Met-Tyr, Gly-Tyr, Phe-Leu, Ile-Phe, Thr-Tyr, Ile-Trp, Tyr-Leu, Ile-Tyr, Val-Phe, Leu-Trp, Val-Trp, Leu-Tyr, and Val-Tyr. Sardines tripeptide is a combination of Ala-Asn-Pro, Ala-Lys-Lys, Arg-Phe-His, Arg-Val-Tyr, Gly-Arg-Pro, Ile-Val-Tyr, Trp-Ile-Thr, Tyr-Val-Pro, and Val-Val-Phe. Sardines tetrapeptide is Gly-Trp-Ala-Pro. Sardines pentapeptide is Asn-Val-Pro-Ile-Tyr.
[0039] Experimental instruments are shown in Table 2.
[0040] Table 2
[0041] Example 1 - Sardine peptide nasal spray (aqueous solution)
[0042] This example provides an aqueous solution-type sardine peptide nasal spray, which comprises a sardine peptide composition and related excipients. The content of each material in the nasal spray is shown in Table 3.
[0043] Table 3
[0044] The preparation method of the sardine peptide nasal spray described in this embodiment comprises the following steps:
[0045] First, accurately weigh each material according to the amount shown in Table 3, dissolve each material in an appropriate amount of water for injection, and after the material is completely dissolved, thoroughly mix the components and add water for injection to the required amount. Measure the solution pH to 5.5-6.5, filter using a 0.22μm microporous filter membrane to obtain a mixed aqueous solution. The mixed aqueous solution is canned in a 30ml quantitative spray container to prepare the aqueous solution type sardine peptide nasal spray. The nasal spray has a spray volume of 50μl per spray.
[0046] Example 2 - Sardine Peptide Nasal Spray (Oil Solution)
[0047] This example provides an oil solution type sardine peptide nasal spray, which comprises a sardine peptide composition and related excipients. The content of each material in the nasal spray is shown in Table 4.
[0048] Table 4
[0049] The preparation method of the sardine peptide nasal spray described in this embodiment comprises the following steps:
[0050] The sardine peptide composition and vitamin E were accurately weighed according to the amounts shown in Table 4. The vitamin E was first dissolved in sesame oil. After the vitamin E was completely dissolved, the sardine peptide composition was suspended in the sesame oil solution to prepare the oil solution type sardine peptide nasal spray.
[0051] After shaking until there is no sediment, the sardine peptide nasal spray bottle is placed into a 20 ml quantitative nasal sprayer, with each spray dose of the sprayer being about 45 μl.
[0052] Example 3 - Sardine Peptide Nasal Spray (Emulsion)
[0053] This example provides an emulsion-type sardine peptide nasal spray, which comprises a sardine peptide composition and related excipients. The content of each material in the nasal spray is shown in Table 5.
[0054] Table 5
[0055] The preparation method of the sardine peptide nasal spray described in this embodiment comprises the following steps:
[0056] First, accurately weigh each material according to the amounts shown in Table 5, dissolve the sardine peptide composition in purified water to form an aqueous phase solution, and then stir and mix vitamin E, soy lecithin, and soybean oil to form an oil phase solution.
[0057] Then, the aqueous phase solution was poured into the oil phase solution and emulsified at a speed of 1000 rpm using a high-speed shear emulsifier to obtain a coarse emulsion; then, a high-pressure homogenizer was used to emulsify at 70°C and a pressure of 1000 bar to obtain an oil-in-water emulsion - an emulsion-type sardine peptide nasal spray.
[0058] The emulsion was placed in a 30 ml metered nasal sprayer so that the spray volume per spray was 45 μl.
[0059] Example 4 - Sardine Peptide Nasal Spray (Oil Solution)
[0060] This example provides an oil-solution type sardine peptide nasal spray, which is similar to the oil-solution type spray described in Example 2, and contains a sardine peptide composition and related excipients, with the only difference being that the content of the sardine peptide composition in the spray is 0.02 g / ml.
[0061] Test Example 1
[0062] The aqueous solution, oil solution and emulsion sardine peptide nasal sprays prepared in Examples 1, 2 and 3 were administered to patients with allergic rhinitis 2 to 3 times a day, and the patient responses were recorded after 7 consecutive days of use.
[0063] A total of 18 subjects participated and were randomly divided into 3 groups, with 6 subjects in each group.
[0064] The first group of 6 subjects used the aqueous solution of sardine peptide nasal spray prepared in Example 1, spraying 1-2 sprays into the nasal cavity each morning and evening, or 1-2 sprays when nasal congestion is caused by external environmental irritation. When spraying, the spray tip should be pointed toward the outside of the nasal cavity.
[0065] The second group of 6 subjects used the oil solution type sardine peptide nasal spray prepared in Example 2. Before use, the spray bottle was shaken up and down 20 times or the bottom of the bottle was observed to be free of sediment. The subjects sprayed 1-2 sprays into the nasal cavity each morning and evening, or 1-2 sprays when nasal congestion was caused by external environmental stimuli. When spraying, the spray tip should be pointed toward the outside of the nasal cavity.
[0066] A third group of six subjects used the emulsion-formulated sardine peptide nasal spray prepared in Example 3. They applied one to two sprays daily, morning and evening, or one to two sprays if nasal congestion was caused by environmental irritation. The spray tip should be pointed toward the outside of the nasal cavity. After seven days of continuous use, the results are shown in Table 6.
[0067] Table 6
[0068] Test Example 2: Study on the toxicity of sardine peptide nasal spray on nasal cilia
[0069] To test whether the sardine composition described in this application is toxic to the nasal mucosa, this test example uses isolated toad palate mucosa as a model to investigate the ciliary toxicity of the sardine peptide nasal spray (oil solution) described in Example 4. The specific experimental method is as follows:
[0070] 1. Materials
[0071] 1.1 Drug testing
[0072] A: normal saline;
[0073] B: refined sesame oil;
[0074] C: Example 4 sardine peptide nasal spray (oil solution);
[0075] D: Example 4 sardine peptide nasal spray (oil solution) + berberine sesame oil suspension (berberine concentration 5 mg / ml).
[0076] 1.2 Instruments
[0077] BM1000 optical microscope.
[0078] 1.3 Animals
[0079] Chinese giant toad (about 50 g / each) was purchased from the Animal Center of Shenyang Pharmaceutical University.
[0080] 2. Experimental methods
[0081] After nasal administration, the nasal mucosa may be affected to varying degrees. Drug toxicity to the nasal mucosa is a key concern for nasal administration. Nasal mucociliary toxicity is assessed by examining the sustained motility of nasal cilia. The main methods include in vitro animal models, in vivo animal models, and in vitro cell culture. The toad palate mucosa is similar to the human nasal mucosa, and in vitro methods are simple and easy to perform. Therefore, this test case uses the in vitro toad palate mucosa as a model to investigate the ciliary toxicity of test drug AD in 1.1.
[0082] 2.1 Isolated toad mandible model
[0083] First, extract the toad's palate mucosa. Use a probe to completely destroy the toad's spine and place it on a wooden board. Cut off the toad's lower jaw and use ophthalmic scissors to carefully remove and separate the toad's palate mucosa to obtain uniform pieces of about 10mm in size. 2The toad's palate mucosa was carefully rinsed with normal saline. The toad's palate was spread on a glass slide with the cilia facing upwards, and the excess saline was aspirated. 80 μL of 4 different solutions (1.1 test drugs AD) were added to the mucosal surface, and the coverslip was gently covered to remove all bubbles. Normal saline was used as a negative control, and twelve groups (n=12) were measured for each sample. The morphology and oscillation of the cilia were observed and recorded under a 25×40 and 25×100 magnification optical microscope, and a video was recorded to observe whether the mucosal state was normal. The specimen was then placed in a chromatography cylinder saturated with water vapor at a room temperature of 20°C. At predetermined time points after administration, the movement of the cilia was observed and recorded under a 25×100 magnification optical microscope.
[0084] 2.2 Evaluation indicators
[0085] The duration from the start of drug administration to the complete cessation of ciliary movement (Persistent Vibration Duration, PVD) is recorded. The toxicity of the tested component is measured by the Percentage of Persistent Vibration (PPV). The larger the PPV, the lower the ciliary toxicity of the component. The formula for PPV is as follows: PPV (%) = T sample / T saline ×100%
[0086] Among them, T sample T is the duration of ciliary beating in the drug-treated group, saline is the duration of ciliary beat in the saline group.
[0087] 2.3 Statistical analysis
[0088] The data are presented as mean ± standard error (n = 12). T-test was used to examine the significant differences in the effects of each group on the duration of ciliary movement of isolated toad palate mucosa, and p < 0.05 was considered significant.
[0089] 3. Results
[0090] Table 7 Effects of drugs on the ciliary movement of toad mandible (n=12, )
[0091] Figure 1 and Table 7 show the effects of different drugs on ciliary motility in the toad's maxillary cilia. Figures 2 and 3 show the ciliary motility at the initial stage and 18 hours after drug administration, respectively.
[0092] In this test example, the nasal mucociliary toxicity of B (refined sesame oil); C (sardine peptide nasal spray (oil solution) of Example 4); and D (sardine peptide nasal spray (oil solution) + berberine sesame oil suspension of Example 4) was evaluated using the isolated toad palate method. A (0.9% saline) was used as a negative control. The results showed that groups B, C, and D had statistically significant effects on the duration of ciliary movement in the isolated toad palate compared with group A (P < 0.05). T-tests showed no significant differences between groups B and C, between groups B and D, or between groups C and D. The duration of ciliary movement was prolonged in groups B, C, and D compared with group A, indicating that groups B, C, and D in this test example did not have acute nasal ciliary toxicity.
[0093] The results of an in vitro study of the nasal mucociliary toxicity of the sardine peptide nasal spray (oil solution) in Example 4, conducted in a toad palate model, showed that the toxicity of the various ingredients in this formulation to the nasal mucosa was lower than that of saline. Specifically, the PVD values in Groups B, C, and D were significantly lower than those in the negative control, saline. Therefore, it can be preliminarily concluded that the sardine peptide nasal spray (oil solution) in Example 4 has a good safety profile.
[0094] Finally, it should be noted that the above is only used to illustrate the technical solution of the present invention and is not limiting. Although the present invention is described in detail with reference to the preferred arrangement scheme, ordinary technicians in this field should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention.
Claims
1. Application of sardine peptide composition in medicine for treating allergic rhinitis.
2. The use according to claim 1, characterized in that: The sardine peptide composition is prepared from sardines by methods including microbial fermentation, acid method, alkali method, electrical method, artificial grafting method, gene expression method and enzymolysis method.
3. The use according to claim 1 or 2, characterized in that: The sardine peptide composition is a mixture of sardine dipeptides to pentapeptides.
4. The use according to claim 3, characterized in that: In the sardine peptide composition, the sardine dipeptide includes Ala-Leu, Lys-Trp, Ala-Trp, Met-Leu, Arg-Tyr, Met-Phe, Gly-Trp, Met-Tyr, Gly-Tyr, Phe-Leu, Ile-Phe, Thr-Tyr, Ile-Trp, Tyr-Leu, Ile-Tyr, Val-Phe, Leu-Trp, Val-Trp, Leu-Tyr, Val-Tyr; sardine tripeptide includes Ala-Asn-Pro, Ala-Lys-Lys, Arg-Phe-His, Arg-Val-Tyr, Gly-Arg-Pro, Ile-Val-Tyr, Trp-Ile-Thr, Tyr-Val-Pro, Val-Val-Phe; sardine tetrapeptide is Gly-Trp-Ala-Pro; sardine pentapeptide is Asn-Val-Pro-Ile-Tyr.
5. The use according to claim 1, characterized in that: The effective dosage of the sardine peptide composition in the diseased body is 0.01-0.03 mg / kg.
6. A composition for preventing and treating allergic rhinitis, characterized in that: The composition comprises a sardine peptide composition and pharmaceutically acceptable excipients.
7. The composition for preventing and treating allergic rhinitis according to claim 6, characterized in that: The sardine peptide composition is a mixture of sardine dipeptides to pentapeptides; wherein the sardine dipeptides include Ala-Leu, Lys-Trp, Ala-Trp, Met-Leu, Arg-Tyr, Met-Phe, Gly-Trp, Met-Tyr, Gly-Tyr, Phe-Leu, Ile-Phe, Thr-Tyr, Ile-Trp, Tyr-Leu, Ile-Tyr, Val-Phe, Leu-Trp, Val-Trp, L eu-Tyr, Val-Tyr; sardine tripeptide includes Ala-Asn-Pro, Ala-Lys-Lys, Arg-Phe-His, Arg-Val-Tyr, Gly-Arg-Pro, Ile-Val-Tyr, Trp-Ile-Thr, Tyr-Val-Pro, Val-Val-Phe; sardine tetrapeptide is Gly-Trp-Ala-Pro; sardine pentapeptide is Asn-Val-Pro-Ile-Tyr.
8. The composition for preventing and treating allergic rhinitis according to claim 6, characterized in that: The mass concentration of the sardine peptide composition in the composition is 0.01% to 50%.
9. The composition for preventing and treating allergic rhinitis according to claim 6, characterized in that: The dosage forms of the composition include mucosal administration preparations, gastrointestinal administration preparations, respiratory tract administration preparations, skin administration preparations, cavity administration preparations, and injection administration preparations.
10. The composition for preventing and treating allergic rhinitis according to claim 6, characterized in that: The allergic rhinitis includes seasonal allergic rhinitis and perennial allergic rhinitis.
Citation Information
Patent Citations
Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
CN108779483A
Application of sardine peptide composition in medicine for treating allergic rhinitis
CN116350746A
Hard-to-digest protein for mitigating allergic symptom
JP2008208097A
Preventive and / or therapeutic drug for allergic rhinitis
JP6671671B1
